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Abstract
Aim To explore in a feasibility study whether ‘e-cycling’ was acceptable to, and could potentially improve the health of,
people with Type 2 diabetes.
Methods Twenty people with Type 2 diabetes were recruited and provided with an electric bicycle for 20 weeks.
Participants completed a submaximal fitness test at baseline and follow-up to measure predicted maximal aerobic power,
and semi-structured interviews were conducted to assess the acceptability of using an electric bicycle. Participants wore a
heart rate monitor and a Global Positioning System (GPS) receiver in the first week of electric bicycle use to measure
their heart-rate during e-cycling.
Results Eighteen participants completed the study, cycling a median (interquartile range) of 21.4 (5.5–37.7) km per
week. Predicted maximal aerobic power increased by 10.9%. Heart rate during electric bicycle journeys was 74.7% of
maximum, compared with 64.3% of maximum when walking. Participants used the electric bicycles for commuting,
shopping and recreation, and expressed how the electric bicycle helped them to overcome barriers to active travel/
cycling, such as hills. Fourteen participants purchased an electric bicycle on study completion.
Conclusions There was evidence that e-cycling was acceptable, could increase fitness and elicited a heart rate that may
lead to improvements in cardiometabolic risk factors in this population. Electric bicycles have potential as a health-
improving intervention in people with Type 2 diabetes.
Diabet. Med. 00: 1–4 (2018)
Introduction
Lifestyle change, including weight loss, improves HbA1c
concentration and other cardiovascular risk factors in people
with Type 2 diabetes [1–3], and can achieve remission to a
non-diabetic state, with remission closely related to the
degree of weight loss [3]. As well as weight loss, increasing
physical activity is a target of such interventions, but success
in changing activity behaviour is often limited [1,2] and any
changes are rarely maintained at initial levels [3]. Physical
activity has independent benefits for health and is important
in the maintenance of weight loss; there is a need, therefore,
to develop acceptable and sustainable physical activity
interventions for people with Type 2 diabetes. This is
challenging, however, because this population is less active
than those without diabetes [4] and responds poorly to
advice to increase physical activity [5].
Active commuting is associated with higher physical
activity [6], weight loss/maintenance [7] and improved
cardiovascular health in the general population [8], and
people with Type 2 diabetes who actively commute are
substantially more active than vehicle users [9]. Prospective
studies comparing the benefits of walking vs cycling suggest
that cycling may provide greater health benefits than walking
in healthy individuals [10], potentially through the higher
intensity of cycling which leads to increased fitness [11];
however, there are a number of barriers, including hilly
routes and perceived effort, which are likely to discourage
people with Type 2 diabetes from cycling.
Electric bicycles (e-bikes) provide graded assistance to the
rider, helping to overcome such barriers, and are increasingly
popular, particularly amongst middle-aged to older adults
[12]. In healthy individuals, riding an e-bike has been shown
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to provide physical activity of at least moderate intensity [>3
metabolic equivalents (METs); heart rate >65%] and gener-
ate improvements in fitness and cardiometabolic risk factors
[13–15]; however, to date, the acceptability/feasibility of ‘e-
cycling’ for people with Type 2 diabetes, or benefits to health
are unknown.
The aim of the present feasibility study was to determine
whether e-cycling was acceptable to people with Type 2
diabetes, to determine whether an e-bike would be used if
provided, to explore outcome measures for future studies and
to describe the experience of using an e-bike to inform
intervention development.
Participants and methods
Ninety-nine people from an observational study of sedentary
behaviour in adults with newly diagnosed Type 2 diabetes
[HbA1c >48 mmol/mol (>6.5%)] were invited to participate,
with 28 expressing interest. A total of 20 people participated
between May and October 2016, of whom 18 completed the
study (Table 1). Ethical approval was granted by the
University of Bristol, Faculty of Health Sciences.
Participants provided their height, weight and clinical
history. Aerobic fitness [predicted maximal aerobic power
(W)] was measured in a sub-maximal test [16] on an upright,
electronically braked cycle ergometer (Schiller ERG911 BP/
LS; Schiller Ltd., Staines, UK). Participants warmed up by
cycling for up to 4 min at a low load, and then cycled at a
cadence of ~60 revolutions/min for three progressive work-
loads, each for 4 min, before cooling down at a light load for
30–60 s.Workloads were selected so that heart rate in the final
stage was ~70–85% of predicted maximal heart rate for age
(HRmax). Heart rate was measured at rest and at the end of the
third minute of each workload. Heart rate during each of the
threeworkloads,workload [Watts (W)], andHRmaxwere used
for estimation of maximal aerobic power (Table 2).
After measurement of baseline variables, participants
individually met a cycle instructor (Life Cycle UK; www.
lifecycleuk.org.uk) to familiarize them with the e-bike and to
provide cycle training on local roads, including guidance on
safe riding practices. Participants were then provided with an
e-bike, helmet, gloves, reflective bib, lock and panniers to use
for 20 weeks. Support was provided for any mechanical
problems encountered by participants. The built-in e-bike
odometer values were recorded at the start and end of the
loan period to measure total distance cycled.
In the first week of cycle usage participants wore a
combined heart rate and accelerometer (ActiHeart; CamN-
tech, Cambridge, UK) and a Global Positioning System (GPS)
receiver (QStarz BT1000X; QStarz International Co. Ltd,
Taipei, Taiwan), recording data every 15 s. Data were
merged by timestamp and visualized in a Geographic
Information System (ArcMap) to identify journeys by e-bike
Table 1 Participant characteristics
Men (n=11) Women (n=7) All (n=18)
Baseline characteristics
Age, years 57.5 (9.3) 59.1 (5.5) 58.1 (7.9)
Height, m 1.78 (0.07) 1.61 (0.06) 1.72 (0.11)
Weight, kg 93.5 (15.6) 81.4 (10.0) 88.8 (14.7)
BMI, kg/m2 29.6 (5.3) 31.2 (2.5) 30.2 (4.4)
Overweight, n (%) 7 (63.6) 2 (28.6) 9 (50.0)
Obese n (%) 4 (36.4) 5 (71.4) 9 (50.0)
Ethnicity: white, n (%) 10 (90.9) 7 (100) 17 (94.4)
Current smoker, n (%) 1 (9.1) 2 (28.6) 3 (16.7)
Employed, n (%) 7 (63.6) 3 (42.9) 10 (55.6)
Retired/not working, n (%) 4 (36.4) 4 (57.1) 8 (44.4)
Duration of diabetes, years 2.2 (0.7) 2.4 (0.6) 2.2 (0.6)
Maximal predicted aerobic power (Wmax); n 193.3 (37.9); 10 137.2 (28.2); 5 174.6 (43.6); 15
HRmax, predicted maximal heart rate for age; Wmax, maximal predicted aerobic power in Watts.
Wmax = workload3 + ([HRmax-HR3] * [workload3 – {(workload1+workload2)/2}]/[HR3 – {(HR1 + HR2)/2}]).
Data are mean (SD) unless stated otherwise.
What’s new?
• No studies to date have explored the utility of electric
bicycle (e-bike) use in people with Type 2 diabetes.
• ‘E-cycling’ elicits a higher heart rate than walking in
people with Type 2 diabetes.
• Preliminary evidence suggests that e-cycling may be
effective in increasing fitness in people with Type 2
diabetes.
• E-cycling was popular, with two-thirds of participants
purchasing an e-bike at the end of the study.
• As people with Type 2 diabetes are a population in
which advice to increase physical activity is often
ineffective, e-cycling has good potential as a health-
improving intervention.
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or foot [6]. For each journey, the mean heart rate and
percentage of HRmax were calculated.
Baseline measures were repeated during the final week of
e-bike use, and semi-structured interviews were conducted to
explore experiences of using the e-bike.
Results
Participants cycled ~21 km per week, with men cycling four
times further than women (Table 2). One collision with a
vehicle occurred, resulting in minor injury. Overall, values
for predicted maximal aerobic power were 10.9% higher at
follow-up, with 12 of 15 participants recording improved
values.
Participants provided 49.2 h of combined heart rate and
GPS data, including a mean (SD) of 4.5 (3.3) e-bike journeys
[mean (SD) distance 7.5 (4.2) km, mean (SD) duration 26.6
(12.6) min] and 3.7 (2.4) walking journeys [mean (SD)
distance 1.0 (1.1) km, mean (SD) duration 16.0 (17.2) min].
Heart rate during e-bike journeys was 74.7% of maximum,
compared with 64.3% of maximum when walking.
Interviews found that e-bikes played an important role in
removing barriers to active travel/cycling and participants
used them for commuting, shopping and recreation. An
advantage was to be able to travel to destinations without
perspiring excessively. The e-bikes enabled many participants
to enjoy being physically active outdoors and to cycle with
partners or friends. The cycle trainers were seen to be
important in developing confidence. Most participants were
reluctant to return their e-bikes at the end of the intervention
period, and 14 purchased the e-bike that they had used or an
alternative brand.
Discussion
The primary aims of the present feasibility study were to
determine whether e-cycling was acceptable to a sample of
people with Type 2 diabetes, and whether an e-bike would be
used if provided. Of 99 people with Type 2 diabetes invited,
20 agreed to participate in the study, suggesting that the
concept was acceptable to a reasonable proportion of this
population. One participant consented but thereafter did not
engage with the study, and a second participant withdrew
during the intervention. Of the remainder, all participants
used the provided e-bike, with most cycling >15 km per week
on average and some cycling substantially further. The
e-bikes were used for a range of purposes, and participants
were positive about the experience of using them. Men used
the e-bikes to a greater extent than women, suggesting that
future interventions will need to be tailored to the different
requirements of both sexes. One participant had a collision
with a motor vehicle, resulting in relatively minor injuries,
but subsequently continued to use the e-bike. There is
evidence that e-cyclists go faster than conventional cyclists,
and that this is associated with higher rates of injury [17].
Any future programme should consider these risks and
ensure, as we did in the present study, that e-bike users are
appropriately trained and provided with safety equipment to
minimize risk.
Although this feasibility study was not powered to
determine any differences in maximal power output, most
participants recorded higher fitness test results at follow-up,
suggesting that e-cycling could be associated with improved
fitness in this population. This observation would be consis-
tent with data from healthy adults, where 6 weeks of daily
commuting was associated with an increase in maximal
power output [18]. In addition, we found that heart rate
during e-cycling was within the range sufficient to increase
cardiorespiratory fitness and was comparable to experimen-
tal studies in younger healthy individuals where e-cycling
elicited a heart rate of 67–69% HRmax over a flat circuit [15]
and 80–84% HRmax on an uphill route [14]. Increased fitness
through e-cycling may be predictive of improvements in
cardiometabolic risk factors [19], with a recent study
reporting improved response to an oral glucose tolerance
test in healthy individuals [20], suggesting that e-cycling may
have potential for improving glucose control in people with
Type 2 diabetes.
The present study has some limitations. Three participants
could not complete the fitness test, although sub-maximal.
Heart rate whilst cycling was measured only in the first week
of the study, and may have been influenced by the unfamil-
iarity of cycling on roads. The GPS receivers were worn by
the participants, and may not have been worn/switched on
all the time. We cannot be certain, therefore, that we
identified all journeys and there is also the possibility that
Table 2 Study outcomes
Men (n=11) Women (n=7) All (n=18)
Median (IQR) total distance cycled, km 456.0 (379.0–1395.0) 111.0 (73.0–252.0) 383.5 (103.0–738.3)
Median (IQR) weekly distance cycled, km 23.1 (21.3–72.9) 6.2 (5.5–14.9) 21.4 (5.5–37.7)
Mean (SD) heart rate during e-cycling journeys, bpm 121.2 (17.2) 132.6 (18.9) 125.2 (18.1)
Mean (SD) heart rate during walking journeys, bpm 103.2 (14.1) 116.5 (16.9) 107.6 (15.8)
Mean (95% CI) change in maximal predicted aerobic power, W 24.0 (–11.7,59.7) 9.1 (–8.17,26.4) 19.1 (–3.9,42.0)
bpm, beats per min; IQR, interquartile range; W, Watts.
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some slow cycling journeys were mis-classified as walking. A
more extended period of GPS recording would be valuable in
future studies to describe journeys in more detail and to
explore potential displacement of motorized travel.
The limited success in increasing physical activity in
randomized controlled trials, and the failure to sustain initial
improvements, indicate the need to identify acceptable and
sustainable physical activity interventions for people with
Type 2 diabetes. The utility, ease and enjoyment of e-cycling
for commuting and carrying out other activities of daily
living that we describe in the present study suggest that it is a
behaviour that could potentially overcome these limitations
by becoming embedded in everyday life, and which has
potential as a health-improving intervention in people with
Type 2 diabetes.
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